Last Updated: May 14, 2026

PHENTERMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Phentermine, and what generic alternatives are available?

Phentermine is a drug marketed by Abc Holding, Able, Aurolife Pharma Llc, Barr, Camall, Chartwell Rx, Duramed Pharms Barr, Elite Labs, Elite Labs Inc, Invagen Pharms, Ivax Pharms, Kvk Tech, Lannett, Lannett Co Inc, Nuvo Pharm, Sandoz, Sun Pharm Industries, Teva, Tg United Inc, Upsher Smith Labs, Usl Pharma, Vitarine, Watson Labs, Zydus Pharms, Actavis Elizabeth, Aurobindo Pharma Ltd, Ingenus Pharms Llc, Kvk Tech Inc, Prinston Inc, Puracap Labs Blu, Sandoz Inc, Sun Pharm Inds Inc, Actavis Labs Fl Inc, Dr Reddys Labs Sa, and Quantum Pharmics. and is included in ninety-one NDAs.

The generic ingredient in PHENTERMINE is phentermine resin complex. There are seventeen drug master file entries for this compound. Additional details are available on the phentermine resin complex profile page.

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for PHENTERMINE?
  • What are the global sales for PHENTERMINE?
  • What is Average Wholesale Price for PHENTERMINE?
Summary for PHENTERMINE
US Patents:0
Applicants:35
NDAs:91
Drug Prices: Drug price information for PHENTERMINE
Drug Sales Revenues: Drug sales revenues for PHENTERMINE
DailyMed Link:PHENTERMINE at DailyMed
Drug patent expirations by year for PHENTERMINE
Drug Prices for PHENTERMINE

See drug prices for PHENTERMINE

Drug Sales Revenue Trends for PHENTERMINE

See drug sales revenues for PHENTERMINE

US Patents and Regulatory Information for PHENTERMINE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chartwell Rx PHENTERMINE HYDROCHLORIDE phentermine hydrochloride TABLET;ORAL 083923-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Actavis Labs Fl Inc PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 204982-004 Jun 25, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Nuvo Pharm PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 205019-001 Dec 5, 2014 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ivax Pharms PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 086329-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Puracap Labs Blu PHENTERMINE HYDROCHLORIDE phentermine hydrochloride TABLET;ORAL 206342-001 Nov 18, 2016 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sandoz PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 088414-001 Oct 19, 1983 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Upsher Smith Labs PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 088430-001 Mar 27, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links